The impact of tamoxifen on apolipoproteins and lipoprotein(a) levels: an updated meta-analysis of randomized controlled trials
Endocrine · 2025
DOI: 10.1007/s12020-024-04128-0 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Endocrine, 2025. Verfasst von Yi Jiang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang, 310012, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Hormonal, Apolipoproteins, Lipoprotein(a), Tamoxifen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE: The existing evidence regarding the impact of tamoxifen on lipoprotein(a) and apolipoproteins remains inconsistent. Therefore, this updated meta-analysis of randomized controlled trials (RCTs) aims to enhance the quality of evidence concerning the effects of tamoxifen on these lipid parameters. METHODS: Eligible RCTs published up to October 2024 were meticulously selected through a comprehensive search. A meta-analysis was then performed using a random-effects model, and results were presented as the weighted mean difference (WMD) with a 95% confidence interval (CI). RESULTS: Findings from the random-effects model revealed an increase in ApoA-I (WMD: 15.22 mg/dL, 95% CI: 6.43-24.01, P = 0.001), alongside decreases in ApoB (WMD: -9.33 mg/dL, 95% CI: -15.46 to -3.19, P = 0.003) and lipoprotein(a) (WMD: -3.35 mg/dL, 95% CI: -5.78 to -0.91, P = 0.007) levels following tamoxifen treatment in women. Subgroup analyses indicated a more significant reduction in lipoprotein(a) levels in RCTs with a duration of ≤24 weeks (WMD: -3.65 mg/dL) and in studies using tamoxifen doses of ≥20 mg/day (WMD: -4.53 mg/dL). CONCLUSION: This meta-analysis provides evidence that tamoxifen leads to a decrease in lipoprotein(a) levels, along with reductions in ApoB and increases in ApoA-I among women.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynecology, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang, 310012, China.
- Shanghai Henlius Biopharmaceutical Co, Ltd, Shanghai, 200233, China.
- Department of Gynaecology and Obstetrics, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200120, China.
- Department of Gynecology and obstetrics, The Second Hospital of Dalian Medical University, Dalian, 116023, China. saya8891@hotmail.com.
Zitieren
APA
Jiang, Y., Zhang, L., Shen, D., & Sun, H. (2025). The impact of tamoxifen on apolipoproteins and lipoprotein(a) levels: an updated meta-analysis of randomized controlled trials. Endocrine. https://doi.org/10.1007/s12020-024-04128-0
Vancouver
Jiang Y, Zhang L, Shen D, Sun H. The impact of tamoxifen on apolipoproteins and lipoprotein(a) levels: an updated meta-analysis of randomized controlled trials. Endocrine. 2025. doi:10.1007/s12020-024-04128-0
BibTeX
@article{Jiang2025,
author = {Jiang, Yi and Zhang, Lantian and Shen, Dongyi and Sun, Haiyan},
title = {The impact of tamoxifen on apolipoproteins and lipoprotein(a) levels: an updated meta-analysis of randomized controlled trials},
journal = {Endocrine},
year = {2025},
doi = {10.1007/s12020-024-04128-0}
}
EUVIMED